Concourse Financial Group Securities, Inc. Galecto, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share
Q2 2024 Jul 23, 2024	BUY	$0.47 - $0.76 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$0.6 - $0.89 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$0.52 - $0.78 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$0.56 - $3.17 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$0.56 - $3.17 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$1.68 - $2.84 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.21 - $2.86 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.06 - $58.5 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$1.59 - $60.0 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.22 - $2.74 $0 - $0
Q1 2022 May 09, 2022	BUY	$1.72 - $3.31 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$2.3 - $3.58 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$3.59 - $5.0 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$4.63 - $8.0 $0 - $0
Q1 2021 May 13, 2021	BUY	$6.08 - $13.25 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$12.51 - $16.84 $0 - $0

Others Institutions Holding GLTO

# of Institutions

Shares Held

21.2K

Call Options Held

Put Options Held

Black Rock Inc. New York, NY

21.2K
Shares

$109,205
0.0% of portfolio

View Full List

About Galecto, Inc.

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $131M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

More about GLTO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account